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Abstract 
In order to develop cost-effective immunomodulator, the recombinant Pichia pastoris were firstly constructed to co-
express porcine IL-2/4/6 genes, and then fermented to feed 45-days Tibetan piglets at different doses to evaluate its 
effects on immunity of piglets to PRRS vaccination, which simultaneously received intramuscular injection of 
inactivated PRRS vaccine. The results were found that the leukocytes, IgG and specific antibody to PRRSV, Th and 
Tc cells increased significantly in the blood of treated piglets in comparison with those of the control (P<0.05); the 
mRNA expression of TLRs (TLR-2, 3, 4, 7, 9), IFN-Ȗ, IL-2, IL-4, IL-6, IL-7, IL-12 and IL-15 genes were elevated 
significantly in the immune cells from the blood of treated piglets (P<0.05). Moreover, the growth of the treated piglets 
also markedly improved whose average net weight gain was significantly higher than the control on 58 days post 
inoculation (P<0.05). These results suggest that the recombinant yeast can effectively enhance the systematic innate 
and adaptive immunity of piglets as well as promote the growth of piglet, which could be further developed as cost-
effective promising immunomodulator to improve the control of pig PRRS disease.  
© 2015  The Authors. Published by Elsevier B.V. 
Selection and peer-review under responsibility of the 8th Vaccine Conference Organizing Committee. 
© 2015 Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license 
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1. Introduction 
Nowadays pigs in intensive feeding farms are susceptible to various pathogens which could not be controlled only 
through vaccination. Viral and bacterial infectious diseases not only bring huge economical loss to pig industry but 
also result in severe public health problems in China. Although vaccines are very important for prevention of pig 
infectious diseases, immune failures of animal frequently happen worldwide due to inadequate immune responses or 
immunosuppression of animals caused by many reasons1, 2. Therefore, development of effective immunomodulator to 
enhance overall immunity of animals is one of practicable and economical choices to prevent animal diseases. 
Cytokines have potent effects on the immune system, regulation haematopoietic cells differentiation, proliferation 
and/or activation. Since the early 1990s, many groups have examined to use cytokines as vaccine adjuvant 3, and have 
evidenced that most cytokines have the ability to modify and re-direct the immune response4. IL-2, IL-4 and IL-6 are 
very important cytokines that play key roles in regulation of innate and adaptive immunity, produced by various cells 
in animal. IL-2 is involved in T-cell proliferation and the induction of T regulatory responses, it not only can enhance 
cellular immune response, but also stimulate proliferation of activated B lymphocytes and induce immunoglobulin 
secretion5; IL-4 can influence humoral and cellular immune responses, such as the production, class switching and 
secretion of immunoglobulin6; IL-6 also has many biological activities that to promote interleukin gene expression, B 
cell differentiation, T cell activation, and play a important role in acute phase reaction7, 8. 
Our previous studies had demonstrated that pig IL-2 or IL-6 with CpG immunostimulatory sequences shuffled 
gene 9,10, or the fusion pig IL-4/6 gene  could effectively enhance the resistance of animals against pathogen infection11, 
12
. The oral administration can elicit both local and systemic immune responses13. Yeast expression systems have a 
number of properties such as high expression levels, adjuvant properties, post-translational modifications, and 
“generally recognized as safe” status, these properties make them have potential advantages as live delivery systems 
for oral inoculation14, 15. In addition, yeast can be internalized by DCs and macrophages and promote presentation of 
antigens16. Moreover, yeast is a good probiotic that can resist the local stresses in gastrointestine, showing high 
survival rate in stomach and small intestine, and can carry out the bioconservation reaction throughout the digestive 
tract17,18,19. Therefore, we suppose that recombinant yeast could be utilized to express cytokine genes to effectively 
promote animal immunity via oral inoculation.  
For sake of developing novel cost-effective immunomodulator for pig, and based on our previous reports, the 
present experiment was conducted to construct recombinant yeast to co-express pig IL-2 gene and fused IL-4/6 gene 
by 2A self-cleavage technique use20, and to evaluate its effect on the immune response and growth of piglets at 
different dose.  
2. Materials and methods 
2.1 The recombinant Pichia pastoris and its construction  
The cDNA of fused pig IL-4/6 gene and IL-2 gene were cloned respectively from recombinant VR1020 plasmids 
containing fused pig IL-4/6 gene or pig IL-2 gene, named VRIL4/6 and VRIL2 preserved in our lab.  
The IL-4/6 gene was firstly cloned into pGAPZĮA (Invitrogen) under the control of GAP promoter with an N-
terminal Į-factor of Saccharomyces cerevisiae as secretion signal. Then, IL-2 gene was linked by 2A-Į fragment that 
contained gene of FMDV 2A peptide and Į-factor gene to guarantee the secreted expression of IL-2. Meanwhile, the 
termination codon of fused pig IL-4/6 gene was removed. Afterwards, the recombinant plasmid (pGAPZĮAJMPIL4/6-
PIL2) was transformed into Escherichia coli (E. coli) DH5Į and positive transformants were screened out on low salt 
Lurea Bertani (LLB) plates containing 25ȝg/ml zeocin, and further identified by direct PCR and sequencing. 
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Eighty microliters of electrocompetent cells of Pichia pastoris SMD1168 was transformed with 10ȝg (in 10ȝl 
sterile water) of AVR-linearized pGAPZĮAJMPIL4/6-PIL2 or AVR-linearized pGAPZĮA vector by 
electroporation according to Invitrogen manual. After transformation, 200ȝl transformed cell was incubated in 1 ml 
of ice-cold 1 M sorbitol, and selected on YPDS plates with 100ȝg/ml zeocin. The positive transformant screened by 
genome analysis and PCR was cultured in 10 ml test tube with 3ml YPD (1% yeast extract, 2% peptone, 2% D-
glucose) medium, 220 rpm shaken for 24h at 30°C, and the culture was preserved in 15% glycerol stored at -20°C 
until use.  
2.2 Expanding culture of the recombinant Pichia pastoris  
All fermentations were carried out in a 10 L seed fermenter and a 100 L fermenter, seed culture for the fermentation 
was started from the preserved recombinant Pichia pastoris and blank Pichia pastoris were thawed and then 30ȝl of 
these strains were respectively inoculated into 10 ml test tube with 3ml YPD medium and 100ȝg/ml zeocin, and 
incubated at 30°C, 220 rpm for 16h in a incubator shaker. Then, the culture of the two Pichia pastoris were 
respectively inoculated in 600 ml YPD medium in 2L flask for overnight at 30°C and 220 rpm.  
The 600 ml culture of recombinant yeast was inoculated into 5.4 liters YPD medium in seed fermenter, 30°C, 
stirrer speed 150 rpm, dissolved oxygen (DO) was set at 30%, when the OD600 was to about 12, inoculated into 100L 
fermenter, consisting of 60L YPD medium and pH 5.8 phosphate buffer, the culture was carried out as the following 
conditions: 30°C, stirrer speed 150 rpm, DO was set at 30%, pH maintained at 5.5 by addition of NH4OH (28%), 
foaming was controlled by using polyether defoamer GPE. Growth was monitored by measuring the OD at 600nm at 
different time points. After the fermentation, 0.3 g/L chitosan solution (food grade, MW: 50000) was added into the 
fermentation broth to flocculate yeast.  
The two Pichia postrois were fermented two batches respectively, and the fermentation broth volume of control 
Pichia pastoris was 40L in each batch. All fermentations in this study were cultured in the same fermentation condition 
as the above-mentioned.  
2.3 Piglets experiment  
Forty healthy 30-day Tibetan piglets were used in this experiment, the body weight of the piglets about 10kg, they 
were randomly divided into four groups: three treated groups A1, A2, A3 and one control group (group C), ten piglets 
per group. All groups had the same forage treatment during the whole experimental period, and the  treated groups 
were directly fed  with recombinant Pichia pastoris fermentation broth preparation according to the different doses, 
continuous feeding 4 weeks, group C was directly fed with the fermentation broth of control Pichia pastoris, 
continuously for 4 weeks, the specific process as shown in table 1. All piglets were vaccinated with inactivated pig 
respiratory and reproduction syndrome (PRRS) vaccine (produced by Chengdu pharmaceutical company, Chengdu, 
China) as the routine protocol of manufacturer.  On days 0, 7, 14, 28, 35, 45 and 58 of the experiment, three to four 
milliliters EDTA-stabilized precaval venous blood sample was collected from each piglet to evaluate the immune 
regulating effect of recombinant Pichia pastoris preparation on piglets. 
        Table 1  Animal experiment grouping and feeding scheme 
group preparation piglet Numbers feeding regime and dose 
A1 Recombinant yeast 10 200ml per piglet; 1 time/day 
A2 Recombinant yeast 10 200ml per piglet; 1 time/2 days 
A3 Recombinant yeast 10 200ml per piglet; 1 time/3 days 
C Control yeast  10 200ml per piglet; 1 time/day 
   Note: The OD600 of the recombinant yeast and control yeast fermentation broth preparation were about 20, the preparations were directly    
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             fed by mixing in forage, and continuously fed four weeks. 
2.4 Piglet body weight  
Body weight of each piglet was measured on days 0, 14, 28, and 58 post inoculation, average weight and net 
weight gain of each group were calculated to evaluate the effect of the recombinant yeast preparation on growth 
performance of piglets. 
2.5 Assay of immune cells quantity in peripheral blood 
The blood samples collected from each piglet 100ȝl per group were used to assay the number of immune cells by 
a routine method. The number of immune cells, platelets and hemoglobin content in precaval venous blood were 
assayed by MIND-RAY BC-3000 blood automatic counting instrument. 
2.6 Measurement of antibody and IgG 
Antibody to PRRS  and pig  IgG measurement ELISA kits were respectively purchased from Keqian Company of 
Wuhan, China and  Bethyl Laboratory, Inc., America. The sandwich ELISA was conducted to detect level of specific 
antibody to PRRSV  and IgG in the sera of piglets according to the manufacturer’s protocols.  
2.7  Assay of Th and Tc cells by flow cytometry 
Mouse against pig CD4 and CD8 mAbs, labeled with phycoerythrin (PE) and spectral red (SPRD) respectively, 
were purchased from Southern Biotech (USA). Fifty ȝl of pig venous blood were mixed with 50ȝl normal saline, and 
then incubated with 2ȝl PE-conjugated anti-CD4 and 2ȝl SPRD labeled anti-CD8 for 20min in the dark. Two ml (10% 
v/v) lysing solution (Becton Dickinson, USA) was then added for 10 min to ensure complete lysis of erythrocytes, 
and surviving cells were washed twice with PBS, with centrifugation between each step for 5min at 500g. Finally, the 
cells were resuspended in 150ȝl PBS and analyzed in a FACScan flow cytometer (Becton Dickinson). 
2.8  Analysis of immune gene expression by quantitative real-time polymerase chain reaction (QRT-PCR)  
The 100ȝl blood samples were mixed with 1ml RNAiso plus (TAKATA), total RNA was extracted and reverse-
transcribed at 42°C for 30 min as the guide (TransGen, TransScriptTM One-Step gDNA Removal and cDNA Synthesis 
SuperMix). And 15 primers for PCR of immune genes were designed and synthesized as shown in table 2 according 
to the related gene sequences in GeneBank.  
PCR was carried out with an initial denaturation for 3 min at 95°C, followed by 42 cycles of 6s at 95°C, 9s at 
optimal annealing temperature, 10s at 72°C, and in each run, the negative control was carried. The PPIA was used as 
the reference gene, and the mRNA levels of immune related genes were calculated in the four groups piglets using the 
geometric means method and the following formula: relative level = 2−ǻǻCt 21. 
 
  Table 2  The primers for QRT-PCR 
Gene Oligonucleotide sequences 5’-3’  Annealing temperature (°C) 
PPIA -F AGACAGCAGAAAACTTCCGTG 51.5 
PPIA -R ACTTGCCACCAGTGCCATTA 
IFN-Ȗ-F GAAGAATTGGAAAGAGGAGAGTGAC 61.5 
IFN-Ȗ-R TCCATGCTCCTTTGAATGGC 
IL-2-F AGCTCTGGAGGGAGTGCTAA 62.0 
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IL-2-R TGTTTCAGATCCCTTTAGTTCCA 
IL-4-F GCTGCCCCAGAGAACACGAC 61.0 
IL-4-R AGGTTCCTGTCAAGTCCGCTC 
IL-6-F TGCAATGAGAAAGGAGATGTGTG 56.5 
IL-6-R CCCAGATTGGAAGCATCCGT 
IL-7-F TCTGTTGCCAGTAGCATCATCT 56.5 
IL-7-R CTATCATCCTGTCCAAGTCATCG 
IL-10-F GCTGGAGGACTTTAAGGGTTAC 60.6 
IL-10-R GAGTTCACGTGCTCCTTGATAT 
IL-12B(p40)-F GAGGTCGTGCTGGAAGCTGTT 62.5 
IL-12B(p40)-R TCTTGGGAGGGTCTGGTTTGA 
IL-15-F GCGATGAAGTGCTTTCTCCTG 57.0 
IL-15-R ACTCAATGGACGATAAACTGCTG 
TLR2-F TGCTGCAAGGTCAACTCTCT 55.7 
TLR2-R CAGCAGGGTCACAAGACAGA 
TLR-3-F GCATTGCCTGGTTTGTTAGTTG 56.0 
TLR-3-R TGTATCAAAAAGAATCACTGGGAG 
TLR-4-F ATATGGCAGAGGTGAAAGCAC 60.2 
TLR-4-R GAAGGCAGAGATGAAAAGGGG 
TLR-7-F ATAGCGAGCATCACTCCAGCC 54.0 
TLR-7-R TAATCTGCTGCCTTCTGGTGC 
TLR-9-F ACAATGACATCCATAGCCGAGT 58.5 
TLR-9-R CAGATCGTTGCCGCTAAAGT 
F: forward.  R: reverse 
2.9  Statistical analysis 
Data of the experimental groups were statistically evaluated by the statistical software program Systat 10 (SPSS). 
Differences between the groups were analyzed by two way ANOVA and Tukey multiple comparison. Data among 
the  groups were considered to be significantly different when P<0.05.  
 
3. Results 
3.1 Identification of recombinant Pichia pastoris 
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The recombinant yeast was screened out via YPD medium containing 100 ȝg/ml Zeocin, and then its RNA was 
extracted and RT-PCR was conducted and analyzed through electrophoresis. The RT-PCR product of the 
recombinant yeast was shown in Fig.1, indicating that fusion pig IL4/6 and IL-2 gene was successfully expressed in 
the recombinant yeast (Fig.1).  
 
Figure 1.  Electrophoresis of RT-PCR of PIL-4/6-PIL2 recombinant yeast (1% agarose gel) 
Lane 1, 2: fragment of RT-PCR of the recombinant; Lane M: Wide Range DNA Marker. 
 
3.2 Body weight change of the piglets 
The effect of recombinant yeast preparation on piglet growth was shown in Fig.2 and table 3. Weight gain of A1 
and A2 groups piglets were obviously higher than group C on days 28 and 58 post inoculation (P< 0.05) (Fig.2). On 
58 days, the increase of average net weight gain of the two groups piglets were 3.88kg and 5.97kg respectively 
compared to group C (table 3). This result demonstrates that recombinant yeast can efficiently improve the growth 
of piglets in dosage dependent way. 
 
Figure 2. The average weight change of pigs. Weight gain of A1 and A2 groups piglets were obviously higher than 
group C on days 28 and 58 post inoculation (P< 0.05). 
 
Table 3 Average net weight gain of pigs (kg) 












3.3 Change of immune cells in peripheral blood 
From 7 to 45 days of the experiment, leukocytes of groups A1 and A2 significantly raised than group C 
(P<0.05), and from 28 to 45 days, the numbers of leukocytes in group A1 were significantly higher (P<0.05) than 
other groups (Fig.3 A). The erythrocytes, platelets and hemoglobin content did not show any obvious differences 
among the four groups (P>0.05), although there were some fluctuations during the experimental period (Fig.3 B, C, 
D).  
 
Group 14d 28d 58d 
A1 3.82 9.57 25.45 
A2 3.27 9.80 27.54 
A3 3.36 7.34 21.40 
C 3.37 6.73 21.57 
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Figure 3. Change of the blood cells in the peripheral blood of experimental pigs. A, Leukocytes of group A1 and A2 
significantly raised than group C from 7 to 45 days (P<0.05), and from 28 to 45 days, the numbers of leukocytes in 
group A1 were significantly higher (P<0.05) than other groups. B, C, D, The erythrocytes, platelets and hemoglobin 
content were some fluctuations during the experimental period, but did not show any obvious differences among the 
four groups (P>0.05). 
3.4. Change of Th and Tc  
The CD4+ and CD8+ T cells significantly increased in the blood of the A1 and A2 groups on 7, 14 and 28 days 
post inoculation compared to the control (P<0.05), and the CD8+ T cells of group A1 seemed to be the highest 
among the three treated groups although their difference were not significant (P>0.05) (Fig.4). 

Figure 4. Th and Tc cells quantity in peripheral blood of experimental pigs. A, B, The CD4+ and CD8+ T cells 
significantly increased in the blood of the A1 and A2 groups on 7, 14 and 28 days post inoculation compared to the 
control (P<0.05). 
 
3.5  Antibody and IgG   
Figure 5  showed that the specific PRRSV antibody and IgG levels in the sera of the treated piglets significantly 
increased than the control group (P <0.05); The difference among the three treated group was not significant 
(P<0.05)(Fig. 5, A,B). 
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Figure 5. Changes of specific antibody to PRRSV and IgG content in the sera of experimental pigs. The level of 
antibody and IgG  significantly increased in the A1 and A2 groups from 14 to 58 days post inoculation compared to 
the control (P<0.05). 
3.6 Change of the immune gene expression 
3.6.1 Change of TLR genes 
To evaluate the effect on pig innate immune system, five TLRs were selected to detect dynamic expression 
change. The results were shown in the Fig.4. The expression levels of TLR-2, TLR-4 and TLR-9 were obviously 
higher in the treated groups compared with group C from 7 to 28 days post inoculation (P<0.05) (Fig.4 A, C, E); 
TLR-3 and TLR-7 also significantly increased during the whole period (P<0.05), and from 7 to 14 days, their levels 
of group A2 were significantly higher than group A1 and A3 (P<0.05) (Fig.4 B, D).  
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Figure 6.  Expression levels of TLR-2, 3, 4, 7 and 9 genes of the experimental pigs. A, C, E, The expression levels 
of TLR-2, TLR-4 and TLR-9 were obviously higher in the treated groups compared with group C from 7 to 28 days 
(P<0.05). B, D, The mRNA levels of TLR-3 and TLR-7 also significantly increased during the whole period 
(P<0.05), and from 7 to 14 days, their levels of group A2 were significantly higher than group A1 and A3 (P<0.05). 
 
3.6.2 Change of the immune memory related genes expression 
To evaluate the immune memory of piglets, the dynamic change of IL-7 and  IL-15 expression levels were 
detected, the results were shown in Fig.7 A, B and C. IL-7 and IL-15 expression levels of the treated groups were 
significantly higher than group C from 7 to 58 days (P<0.05). 
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Fig.7  Expression levels of IL-7 and IL-15 genes of the experimental pigs. A, B, The expression levels of IL-7 and 
IL-15 were significantly higher than group C from 7 to 58 days in treated groups (P<0.05).  
3.6.3 Change of cytokine genes expression 
IL-2, IL-4, IL-6, IL-12 and IFN-Ȗ from various immune cells, are pivotal in determining the effectiveness of pig 
immune responses. As shown in Fig.8 A, B, C, D, E, the expression of IL-2, IL-4 and IFN-Ȗ genes of treated groups 
significantly increased from 7 to 45 days compared to those of the control (P<0.05), and the expression of IL-2 and 
IFN-Ȗ respectively reached the maximum on day 7 and day 14. Meanwhile, the IL-6 and IL-12 expression levels of 
treated groups were obviously higher than group C from 7 to 35 days, and the IL-6 expression level of group A1 was 
significantly higher than the other groups (P<0.05). In addition, the IL-10 expression levels of group A1 was 
significantly higher than group C from 7 to 14 days and so was the group A2 on 7 days (P<0.05) (Fig.8 F). 
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Figure 8.  Expression levels of IL-2, IL-4, IL-6, IL-10, IL-12 and IFN-Ȗ genes of the experimental pigs. A, C, D, the 
expression of IL-2, IL-4 and IFN-Ȗ genes of treated groups significantly increased from 7 to 45 days compared with 
those of the control (P<0.05). B, E, the IL-6 and IL-12 expression levels of treated groups were obviously higher than 
group C from 7 to 35 days, and the IL-6 expression level of group A1 was significantly higher than the other groups 
(P<0.05). F,  the IL-10 expression levels of group A1 was significantly higher than group C from 7 to 14 days and so 
was the group A2 on 7 days (P<0.05). 
4. Discussion 
Cytokines are vital regulators of immune functions, and mainly produced by various immune system can bind to 
specific receptors on the surface of their target cells, and induce intracellular signaling pathways that trigger a series 
of biological processes, such as cell proliferation, activation and differentiation. At present, many cytokines have been 
used as adjuvants to enhance primary and memory immune responses23. IL-2, majorly secreted by Th0 cells, serves 
as a key cytokine to support the growth and proliferation of T cells and NK cells24, and also to stimulate proliferation 
of activated B-lymphocytes and to induce immunoglobulin secretion5. IL-4 is primarily produced by Th2 cells, it is 
able to promote B cell responses and influence immunoglobulin class switching in B cells6. IL-6 is a multifunctional 
cytokine with a wide range of biological activities in immune regulation, hematopoiesis and inflammation. Our 
previous study demonstrated that co-expression of pIL4/6 fused gene and IL-2 shuffled gene in vivo could elicit 
significant enhancement of mice immunity compared with the individual genes (data in our lab).  
Therefore, in this study, the recombinant Pichia pastoris co-expressing porcine interleukin-2 and interleukin-4/6 
was employed to evaluate whether it could promote the immunity and growth of piglets through oral inoculation. 
Interestingly, we observed that the recombinant yeast efficiently improved the growth of A1 and A2 piglets in suitable 
dosage (P<0.05). Early works had recognized that cytokines not only regulate immune function but also modify the 
growth performance, and adipose tissue can respond to cytokines signals and produce a number of metabolic 
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regulators to regulate growth25, 26, 27. Therefore, this may be correlated with the “reprogramming” of metabolism 
mediated by cytokines increments. 
Moreover, feeding the recombinant yeast significantly elevated the expression levels of the five TLRs and the 
important immune genes such as IL-2, IL-4, IL-6, IL-7, IL-12 and IL-15 in comparison with those of group C (P<0.05); 
Meanwhile, the feedings also elicited obvious increase of Th and Tc  cells as well as specific antibody and IgG content  
in the blood of the treated piglets (P<0.05), which maybe resulted from the enhancement of  cytokines production and 
better cellular and humoral immunity to vaccination with PRRSV. Furthermore, the immunity of group A1 and A2 
are better than the other groups, and it is probably related with the stimulation increment of recombinant yeast.  
TLRs are first line of immune system to detect pathogen infection, they play a central roles in the innate immune 
response by recognizing conserved molecules patterns of diverse pathogens, and also participate in activation the 
pathogen-specific humoral and cellular adaptive immune responses 22, 28. IL-7 and IL-15 serve as critical regulators 
that mediate pleiotropic effects on multiple cell types, they are required for the development, proliferation, 
differentiation and survival of specific immune cells29, especially for immunological memory cells30, 31.  Furthermore, 
IL-10, IL-12 and IFN-Ȗ also play an important role in animal immune response. Therefore, significant increase of 
these genes expression and leukocytes in the blood indicate that the recombinant yeast can effectively strengthen 
innate and adaptive immune response of piglets. Besides, these results also provide experimental support for the 
possible application of the recombinant Pichia pastoris in oral feeding way19. 
Briefly, our results confirm that the recombinant yeast co-expressing porcine IL-2 and IL-4/6 is a novel cost-
effective immunomodulator that can not only markedly enhance the innate and adaptive immunity of piglet but also 
improve piglet growth, which can facilitate the development of an easy and cost-effective  immunomodulator for 
better control and prevention of pig infectious diseases in the future.  
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